Arbutus Biopharma develops therapies aimed at a functional cure for chronic hepatitis B, led by the RNAi candidate imdusiran (AB-729) and complementary agents such as an oral PD-L1 inhibitor. The company focuses on multi-mechanism combinations that suppress the virus, reduce viral antigens, and help restore immune control. It is clinical-stage and builds on earlier work in viral therapeutics and related nucleic-acid delivery intellectual property.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.8 | — | -24.5 | — |
| Q2 2025 | 10.7 | — | 2.5 | — |
| Q3 2025 | 0.5 | — | -7.7 | — |
| Q4 2025 | 1.1 | — | -3.8 | — |
| Q1 2026 | 179.1 | 10,054.5% | 169.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MetroCity Bankshares, Inc. (MCBS), CNB Financial Corporation (CCNE), Lexicon Pharmaceuticals, Inc. (LXRX), Candel Therapeutics, Inc. (CADL), Immix Biopharma, Inc. (IMMX), Horizon Bancorp, Inc. (HBNC)